FIV as a Model for HIV Treatment

  • Katrin Hartmann
  • Christiane Stengel
Part of the Infectious Diseases and Pathogenesis book series (IAPA)


Human immunodeficiency virus (HIV) infection shares close similarities with feline immunodeficiency virus (FIV) infection in respect to molecular structure, replication properties, and pathogenesis of disease. FIV causes an immunodeficiency syndrome in domestic cats comparable to acquired immunodeficiency syndrome (AIDS) in humans.


Nucleoside Analogue Fusion Inhibitor Lassa Fever Feline Infectious Peritonitis Inhibit Reverse Transcriptase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arai, M., Darman, J., Lewis, A., Yamamoto, J. K., and Darmen, J., 2000, The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats, Vet Immunol Immunopathol 77:71–92.PubMedCrossRefGoogle Scholar
  2. Arai, M., Earl, D. D., and Yamamoto, J. K., 2002, Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 85:189–204.PubMedCrossRefGoogle Scholar
  3. Auwerx, J., Esnouf, R., DeClercq, E., and Balzarini, J., 2004, Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors, Mol Pharmacol 65:244–251.PubMedCrossRefGoogle Scholar
  4. Balzarini, J., Egberink, H., Hartmann, K., Cahard, D., Vahlenkamp, T., Thormar, H., DeClercq, E., and McGuigan, C., 1996, Antiretrovirus specificity and intracellular metabolism of 2′, 3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate trimester prodrug So324, Mol Pharmacol 50:1207–1213.PubMedGoogle Scholar
  5. Barr, A. C., Phillips, T. R., 2000, FIV and FIV-related diseases, in: Textbook of Veterinary Internal Medicine, 5th ed., S. J. Ettinger, E. C. Feldman, eds., WB Saunders, Philadelphia, pp. 433–438.Google Scholar
  6. Beatty, J., Terry, A., MacDonald, J., Gault, E., Cevario, S., O’Brien, S. J., Cameron, E., and Neil, J. C., 2002, Feline immunodeficiency virus integration in B-cell lymphoma identifies a candidate tumor suppressor gene on human chromosome 15q15, Cancer Res 62:7175–7180.PubMedGoogle Scholar
  7. Berson, J. F., Long, D., Doranz, B. J., Rucker, J., Jirik, F. R., and Doms, R. W., 1996, A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains, J Virol 70:6288–6295.PubMedGoogle Scholar
  8. Bisset, L. R., Lutz, H., Boni, J., Hofmann-Lehmann, R., Luthy, R., and Schupbach, J., 2002, Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication, Antiviral Res 53:35–45.PubMedCrossRefGoogle Scholar
  9. Callanan, J. J., Jones, B. A., Irvine, J., Willett, B. J., McCandlish, I. A., and Jarrett, O., 1996, Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections, Vet Pathol 33:264–272.PubMedCrossRefGoogle Scholar
  10. Cantell, K., and Pyhala, L., 1973, Circulating interferon in rabbits after administration of human interferon by different routes, J Gen Virol 20:97–104.PubMedGoogle Scholar
  11. Cotter, S. M., 1991, Management of healthy feline leukemia virus-positive cats, J Am Vet Med Assoc 199:1470–1473.PubMedGoogle Scholar
  12. Cummins, J. M., Beilharz, M. W., and Krakowka, S., 1999, Oral use of interferon. J Interferon Cytokine Res 19:853–857.PubMedCrossRefGoogle Scholar
  13. DeClercq, E., Schols, D., Bridger, G., and Henson, G., 2001, CXCR4 receptor antagonist, AMD3100, is a potent inhibitor of HIV infection, Abstracts of Papers American Chemical Society 221:Medi24.Google Scholar
  14. DeParseval, A., Lerner, D. L., Borrow, P., Willett, B. J., and Elder, J. H., 1997, Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding, J Virol 71:5742–5749.Google Scholar
  15. DeParseval, A., Chatterji, U., Sun, P., and Elder, J. H., 2004, Feline immunodeficiency virus targets activated CD4+ T-cells by using CD134 as a binding receptor, Proc Natl Acad Sci USA 101:13044–13049.CrossRefGoogle Scholar
  16. Diehl, L. J., Mathiason-Dubard, C. K., O’Neil, L. L., and Hoover, E. A., 1995, Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR, J Virol 69:2328–2332.PubMedGoogle Scholar
  17. Diehl, L. J., Mathiason-Dubard, C. K., O’Neil, L. L., and Hoover, E. A., 1996, Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection, J Virol 70:2503–2507.PubMedGoogle Scholar
  18. Dillon, R., 1984, Feline dirofilariasis, Vet Clin North Am Small Anim Pract 14:1185–1199.PubMedGoogle Scholar
  19. Donzella, G. A., Schols, D., Lin, S. W., Este, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., De Clercq, E., and Moore, J. P., 1998, AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor, Nat Med 4:72–77.PubMedCrossRefGoogle Scholar
  20. Dow, S. W., Poss, M. L., and Hoover, E. A., 1990, Feline immunodeficiency virus: a neurotropic lentivirus, J Acquir Immune Defic Syndr 3:658–668.PubMedGoogle Scholar
  21. Egberink, H. F., DeClercq, E., VanVliet, A. L., Balzarini, J., Bridger, G. J., Henson, G., Horzinek, M. C., and Schols, D., 1999, Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication, J Virol 73:6346–6352.PubMedGoogle Scholar
  22. Eron, J. J., and Hogan, C. M., 2002, Entry and fusion inhibitors: an update, PRN Notebook 7:16–22.Google Scholar
  23. Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A., 1996, HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor, Science 272:872–877.PubMedCrossRefGoogle Scholar
  24. Fischl, M. A., Richman, D. D., Hansen. N., Collier, A. C., Carey, J. T., Para, M. F., Hardy, W. D., Dolin, R., Powderly, W. G., Allan, J. D., Wong, B., Merigan, T. C., McAuliffe, V. J., Hyslop, N. E., Rhame, F. S., Balfour, H. H., Spector, S. A., Volberding, P., Pettinelli, C., and Anderson, J., 1990, The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection, Ann Intern Med 112:727–737.PubMedGoogle Scholar
  25. Fogleman, R. W., Chapdelaine, J. M., Carpenter, R. H., McAnalley, B. H., 1992, Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet Hum Toxicol 34:201–205.PubMedGoogle Scholar
  26. Frey, S. C., Hoover, E. A., and Mullins, J. I., 2001, Feline immunodeficiency virus cell entry, J Virol 75:5433–5440.PubMedCrossRefGoogle Scholar
  27. Garg, H., Fuller, F. J., and Tompkins, W. A., 2004, Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology 321:274–286.PubMedCrossRefGoogle Scholar
  28. Giannecchini, S., DiFenza, A., D’Ursi, A. M., Matteucci, D., Rovero, P., and Bendinelli, M., 2003, Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein, J Virol 77:3724–3733.PubMedCrossRefGoogle Scholar
  29. Gobert, J. M., Remington, K. M., Zhu, Y. Q., and North, T. W., 1994, Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3′-azido-3′-deoxythymidine, Antimicrob Agents Chemother 38:861–864.PubMedGoogle Scholar
  30. Greene, C. E., 1998, Immunoprophylaxis and immunotherapy, in: Infectious Diseases of the Dog and Cat, 2nd ed., C. E. Greene, ed., WB Saunders, Philadelphia, pp. 717–750.Google Scholar
  31. Greene, C. E., and Watson, A. D. J., 1998a, Antiviral drugs, in: Infectious Diseases of the Dog and Cat, 2nd ed., C. E. Greene, ed., WB Saunders, Philadelphia, pp. 6–9.Google Scholar
  32. Greene, C. E., and Watson, A. D. J., 1998b, Antimicrobial drug formulary, in: Infectious Diseases of the Dog and Cat, 2nd ed., C. E. Greene, ed., WB Saunders, Philadelphia, pp. 790–919.Google Scholar
  33. Gregory, C. R., Barlough, J. E., Clark, R., Griffey, S. M., Patz, J. D., Jardieu, P., and Pedersen, N. C., 1997, Effects of insulin-like growth factor-1 and AZT in cats experimentally infected with FIV, Feline Pract 25:23–31.Google Scholar
  34. Hara, Y., Ishida, T., Ejima, H., Tagawa, M., Motoyoshi, S., Tomoda, I., Shimizu, M., and Shichinohe, K., 1990, Decrease in mitogen-induced lymphocyte proliferative responses in cats infected with feline immunodeficiency virus, Jpn J Vet Sci 52:573–591.Google Scholar
  35. Harris, C., Pierce, K., King, G., Yates, K. M., Hall, J., and Tizard, I., 1991, Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms, Mol Biother 3:207–213.PubMedGoogle Scholar
  36. Hartmann, K., 1995a, AZT in the treatment of feline immunodeficiency virus infection. Part 1, Feline Pract 23:16–21.Google Scholar
  37. Hartmann, K., 1995b, AZT in the treatment of feline immunodeficiency virus infection. Part 2, Feline Pract 23:13–20.Google Scholar
  38. Hartmann, K., 1998, Feline immunodeficiency virus infection, Brit Vet J 155:123–137.CrossRefGoogle Scholar
  39. Hartmann, K., and Kuffer, M., 1998, Karnofsky’s score modified for cats, Eur J Med Res 3: 95–98.PubMedGoogle Scholar
  40. Hartmann, K., Stengel, S., Klein, D., Egberink, H., and Balzarini, J., 2002, Efficacy of the chemokine receptor inhibitor 1,1′-bis-1,4,8,11-tetraazacyclotetradekan against feline immunodeficiency virus infection, in: Abstracts 6th International Feline Retrovirus Research Symposium, Amelia Island, USA.Google Scholar
  41. Hori, T., Sakaida, H., Sato, A., Nakajima, T., Shida, H., Yoshie, O., and Uchiyama, T., 1998, Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic (correction of T-cell-tropic) HIV-1 by three different monoclonal antibodies, J Immunol 160:180–188.PubMedGoogle Scholar
  42. Hsu, W. H., 1980, Toxicity and drug interactions of levamisole, J Am Vet Med Assoc 176:1166–1169.PubMedGoogle Scholar
  43. Jordan, H. L., Pereira, A. S., Cohen, M. S., and Kashuba, A. D., 2001, Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma, Antimicrob Agents Chemother 45:2173–2176.PubMedCrossRefGoogle Scholar
  44. Karnofsky, D. A., Abelmann, W. H., Craver, L. F., and Burchenal, J. H., 1948, The use of the nitrogen mustards in the palliative treatment of carcinoma, Cancer 11:634–656.CrossRefGoogle Scholar
  45. Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., Valentine, F., Saag, M. S., Nelson, E. L., Sista, P. R., and Dusek, A., 2002, The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults, AIDS Res Hum Retroviruses 18:685–693.PubMedCrossRefGoogle Scholar
  46. King, G. K., Yates, K. M., Greenlee, P. G., Pierce, K. R., Ford, C. R., McAnalley, B. H., and Tizard, I. R., 1995, The effect of acemannan immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas, J Am Anim Hosp Assoc 31:439–447.PubMedGoogle Scholar
  47. Klein, D., Janda, P., Steinborn, R., Mueller, M., Salmons, B., and Guenzburg, W. H., 1999, Proviral load determination of different feline immunodeficiency virus isolates using real-time polymerase chain reaction: influence of mismatches on quantification, Electrophoresis 20:291–299.PubMedCrossRefGoogle Scholar
  48. Koech, D. K., and Obel, A. O., 1990, Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS), East Afr Med J 67:64–70.Google Scholar
  49. Kraft, W., and Kuffer, M., 1995, Treatment of severe neutropenias in dogs and cats with filgrastim, Tierärztl Prax 23:609–613.PubMedGoogle Scholar
  50. Lawrence, C. E., Callanan, J. J., Willett, B. J., and Jarrett, O., 1995, Cytokine production by cats infected with feline immunodeficiency virus: a longitudinal study, Immunology 85:568–574.PubMedGoogle Scholar
  51. Lehmann, R., Joller, H., Haagmans, B. L., and Lutz, H., 1992, Tumornecrosis faktor α levels in cats experimentally infected with feline immunodeficiency virus: effects on immunization and feline leukemia virus infection, Vet Immunol Immunopathol 35:61–69.PubMedCrossRefGoogle Scholar
  52. Levy, J. K., 2000, CVT update: feline immunodeficiency virus, in: Kirk’s Current Veterinary Therapy XIII. Small Animal Practice, J. D. Bonagura, ed., WB Saunders, Philadelphia, pp. 284–288.Google Scholar
  53. MacEwen, E. G., Hayes, A. A., Mooney, S., Patnaik, A. K., Harvey, H. J., Passe, S., and Hardy, W. D. Jr., 1984, Evaluation of effect of levamisole on feline mammary cancer, J Biol Response Mod 3:541–546.PubMedGoogle Scholar
  54. Maynard, L., DeMari, K., and Lebreux, B., 2000, Efficacy of a recombinant feline omega interferon in the treatment of symptomatic FeLV-or FeLV-and FIV-positive cats, in: Abstracts 10th Annual Congress of the European Society of Veterinary Internal Medicine (ESVIM), Neuchâtel, Switzerland.Google Scholar
  55. Medinas, R. J., Lambert, D. M., and Tompkins, W. A., 2002, C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread, J Virol 76:9079–9086.PubMedCrossRefGoogle Scholar
  56. Medlin, H. K., Zhu, Y. Q., Remington, K. M., Phillips, T. R., and North, T. W., 1996, Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2′,3′-dideoxycytidine, Antimicrob Agents Chemother 40:953–957.PubMedGoogle Scholar
  57. Ogilvie, G. K., 1995, Hematopoietic growth factors: frontiers for cure, Vet Clin North Am Small Anim Pract 25:1441–1456.PubMedGoogle Scholar
  58. Ohashi, T., Goitsuka, R., Watari, T., Tsujimoto, H., and Hasegawa, A., 1992, Elevation of feline interleukin 6-like activity in feline immunodeficiency virus infection, Clin Immunol Immunopathol 65:207–211.PubMedCrossRefGoogle Scholar
  59. Phillips, T. R., Prospero Garcia, O., Puaoi, D. L., Lerner, D. L., Fox, H. S., Olmsted, R. A., Bloom, F. E., Henriksen, S. J., and Elder, J. H., 1994, Neurological abnormalities associated with feline immunodeficiency virus infection, J Gen Virol 75:979–987.PubMedCrossRefGoogle Scholar
  60. Povey, R. C., 1978, Effect of orally administered ribavirin on experimental feline calicivirus infection in cats, Am J Vet Res 39:1337–1341.PubMedGoogle Scholar
  61. Priosoeryanto, B. P., Tateyama, S., Yamaguchi, R., and Uchida, K., 1995, Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro, Can J Vet Res 59:67–69.PubMedGoogle Scholar
  62. Reinemeyer, C. R., Faulkner, C. T., Assadi-Rad, A. M., Burr, J. H., and Patton, S., 1995, Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups, J Am Vet Med Assoc 206:1710–1715.PubMedGoogle Scholar
  63. Reubel, G. H., Gregg, A. D., George, J. W., Barlough, J. E., and Pedersen, N. C., 1994, Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats, J Acquir Immune Defic Syndr 7:1013–1015.Google Scholar
  64. Richardson, J., Pancino, G., Merat, R., Leste-Lasserre, T., Moraillon, A., Schneider-Mergener, J., Alizon, M., Sonigo, P., and Heveker, N., 1999, Shared usage of the chemokine receptor CXCR4 by primary and laboratory-adapted strains of feline immunodeficiency virus, J Virol 73:3661–3671.PubMedGoogle Scholar
  65. Rimmelzwaan, G. F., Siebelink, K. H., Broos, H., Drost, G. A., Weijer, K., van Herwijnen, R., and Osterhaus, A. D., 1994, Gag-and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus, Vet Microbio 39:153–165.CrossRefGoogle Scholar
  66. Ryrfeldt, A., Nordgren, T., and Lundstrom, J., 1992, Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs, Fundam Appl Toxicol 18:126–130.PubMedCrossRefGoogle Scholar
  67. Sato, R., Inanami, O., Tanaka, Y., Takase, M., and Naito, Y., 1996, Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats, Am J Vet Res 57:1443–1446.PubMedGoogle Scholar
  68. Scadden, D. T., Zon, L. I., and Groopman, J. E., 1989, Pathophysiology and management of HIV-associated hematologic disorders, Blood 74:1455–1463.PubMedGoogle Scholar
  69. Schellekens, H., Geelen, G., Meritet, J.-F., Maury, C., and Tovey, M. G., 2001, Oromucosal interferon therapy: Relationship between antiviral activity and viral load, J Interferon Cytokine Res 21:575–581.PubMedCrossRefGoogle Scholar
  70. Sellon, R. K., 1998, Feline immunodeficiency virus infection, in: Infectious Diseases of the Dog and Cat, 2nd ed., C. E. Greene, ed., WB Saunders, Philadelphia, pp. 84–96.Google Scholar
  71. Shaw, S. E., Robertson, I. D., Robinson, W. F., Alexander, R., and Sutherland, R. J., 1990, Feline immunodeficiency virus: disease associations, Australian Vet Pract 20:194–198.Google Scholar
  72. Smith, R. A., Remington, K. M., Preston, B. D., Schinazi, R. F., and North, T. W., 1998, A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (−)-beta-2′,3′-dideoxy-3′-thiacytidine and 3′-azido-3′-deoxythymidine, J Virol 72:2335–2340.PubMedGoogle Scholar
  73. Smyth, N. R., McCracken, C., Gaskell, R. M., Cameron, J. M., Coates, J. A., Gaskell, C. J., Hart, C. A., and Bennett, M., 1994, Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents, J Antimicrob Chemother 34:589–594.PubMedCrossRefGoogle Scholar
  74. Stengel, C., Klein, D., Egberink, H., Balzarini, J., and Hartmann, K., 2003, Placebo-controlled double-blind treatment study in naturally feline immunodeficiency virus-infected cats using the chemokine receptor inhibitor 1,1′-bis-1,4,8,11-tetraazacyclo-tetradekan (AMD3100), in: Research Abstracts of the 21st Annual American College of Veterinary Internal Medicine (ACVIM) Forum, Charlotte, NC.Google Scholar
  75. Swenson, C. L., Sams, R. A., Polas, P. J., Michael, D. F., and Mathes, L. E., 1990, Age-related differences in pharmacokinetics of phosphonoformate in cats, Antimicrob Agents Chemother 34:871–874.PubMedGoogle Scholar
  76. Swenson, C. L., Weisbrode, S. E., Nagode, L. A., Hayes, K. A., Steinmeyer, C. L., and Mathes, L. E., 1991, Age-related differences in phosphonoformate-induced bone toxicity in cats, Calcif Tissue Int 48:353–361.PubMedCrossRefGoogle Scholar
  77. Tanabe, T., and Yamamoto, J. K., 2001, Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma, J Interferon Cytokine Res 21:1039–1046.PubMedCrossRefGoogle Scholar
  78. Taniguchi, A., Ishida, T., Konno, A., Washizu, T., and Tomoda, I., 1990, Altered mitogen response of peripheral blood lymphocytes in different stages of feline immunodeficiency virus infection, Jpn J Vet Sci 52:513–518.Google Scholar
  79. Tateyama, S., Priosoeryanto, B. P., Yamaguchi, R., Uchida, K., Ogiwara, K., and Suchiya, A. T., 1995, In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours, Res Vet Sci 59:275–277.PubMedCrossRefGoogle Scholar
  80. Terry, A., Callanan, J. J., Fulton, R., Jarrett, O., and Neil, J., 1995, Molecular analysis of tumours from feline immunodeficiency virus (FIV)-infected cats: an indirect role for FIV? Int J Cancer 61:227–232.PubMedCrossRefGoogle Scholar
  81. Tompkins, W. A., 1999, Immunomodulation and therapeutic effects of the oral use of interferon-α: Mechanism of action, J Interferon Cytokine Res 19:817–828.PubMedCrossRefGoogle Scholar
  82. Torten, M., Franchini, M., Barlough, J. E., George, J. W., Mozes, E., Lutz, H., and Pedersen, N. C., 1991, Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus, J Virol 65:2225–2230.PubMedGoogle Scholar
  83. Torten, M., Rideout, B. A., Luciw, P. A., Sparger, E. E., and Pedersen, N. C., 1990, Coinfection of cats with feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) enhances the severity of FIV infection and affects the distribution of FIV DNA in various tissues, in: Animal Models in AIDS, H. Schellekens, M. C. Horzinek, eds., Elsevier Science Publishers, Amsterdam, pp. 209–219.Google Scholar
  84. Ueda, Y., Sakurai, T., and Yanai, A., 1993a, Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product, J Vet Med Sci 55:251–258.PubMedGoogle Scholar
  85. Ueda, Y., Sakurai, T., Kasama, K., Satoh, Y., Atsumi, K., Hanawa, S., Uchino, T., and Yanai, A., 1993b, Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′-oligoadenylate synthetase activity in the cat, J Vet Med Sci 55:1–6.PubMedGoogle Scholar
  86. Weiss, R. C., Cox, N. R., and Boudreaux, M. K., 1993a, Toxicologic effects of ribavirin in cats, J Vet Pharmacol Ther 16:301–316.PubMedGoogle Scholar
  87. Weiss, R. C., Cox, N. R., and Martinez, M. L., 1993b, Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis, Res Vet Sci 55:162–172.PubMedGoogle Scholar
  88. Willett, B. J., Cannon, C. A., and Hosie, M. J., 2002, Upregulation of surface feline CXCR4 expression following ectopic expression of CCR5: implications for studies of the cell tropism of feline immunodeficiency virus, J Virol 76:9242–9252.PubMedCrossRefGoogle Scholar
  89. Willett, B. J., Picard, L., Hosie, M. J., Turner, J. D., Adema, K., and Clapham, P. R., 1997, Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses, J Virol 71:6407–6415.PubMedGoogle Scholar
  90. Woo, J. C., Dean, G. A., Lavoy, A., Clark, R., and Moore, P. F., 1999, Investigation of recombinant human insulin-like growth factor type I in thymus regeneration in the acute stage of experimental FIV infection in juvenile cats, AIDS Res Hum Retroviruses 15:1377–1388.PubMedCrossRefGoogle Scholar
  91. Yamauchi, K., Wakabayashi, H., Hashimoto, S., Teraguchi, S., Hayasawa, H., and Tomita, M., 1998, Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers, Adv Exp Med Biol 443:261–165.PubMedGoogle Scholar
  92. Yates, K. M., Rosenberg, L. J., Harris, C. K., Bronstad, D. C., King, G. K., Biehle, G. A., Walker, B., Ford, C. R., Hall, J. E., and Tizard, I. R., 1992, Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus, Vet Immunol Immunopathol 35:177–189.PubMedCrossRefGoogle Scholar
  93. Yu, N., Billaud, J. N., and Phillips, T. R., 1998, Effects of feline immunodeficiency virus on astrocyte glutamate uptake: implications for lentivirus-induced central nervous system diseases, Proc Natl Acad Sci USA 95:2624–2629.PubMedCrossRefGoogle Scholar
  94. Zeidner, N. S., Myles, M. H., Mathiason-DuBard, C. K., Dreitz, M. J., Mullins, J. I., and Hoover, E. A., 1990, Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome, Antimicrob Agents Chemother 34:1749–1756.PubMedGoogle Scholar
  95. Zenger, E., Collisson, E. W., Barhoumi, R., Burghardt, R. C., Danave, I. R., and Tiffany Castiglioni, T. E., 1995, Laser cytometric analysis of FIV-induced injury in astroglia, Glia 13:92–100.PubMedCrossRefGoogle Scholar
  96. Zhang, L., He, T., Huang, Y., Chen, Z., Guo, Y., Wu, S., Kunstman, K. J., Brown, R. C., Phair, J. P., Neumann, A. U., Ho, D. D., and Wolinsky, S. M., 1998, Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1, J Virol 72:9307–9312.PubMedGoogle Scholar
  97. Zhu, Y. Q., Remington, K. M., and North, T. W., 1996, Mutants of feline immunodeficiency virus resistant to 2′3′dideoxy-2′3′-didehydrothymidine, Antimicrob Agents Chemother 40:1983–1987.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Katrin Hartmann
    • 1
  • Christiane Stengel
    • 1
  1. 1.Medizinische KleintierklinikLudwig-Maximilians-Universität MünchenGermany

Personalised recommendations